Evaluation of the drug–drug interaction potential of brigatinib using a physiologically‐based pharmacokinetic modeling approach

Evaluation of the drug–drug interaction potential of brigatinib using a physiologically‐based pharmacokinetic modeling approach

Abstract Brigatinib is an oral anaplastic lymphoma kinase (ALK) inhibitor approved for the treatment of ALK‐positive metastatic non‐small cell lung cancer. In vitro studies indicated that brigatinib is primarily metabolized by CYP2C8 and CYP3A4 and inhibits P‐gp, BCRP, OCT1, MATE1, and MATE2K. Clini...

Full description

Bibliographic Details
Main Authors:	Michael J. Hanley, Karen Rowland Yeo, Meera Tugnait, Shinji Iwasaki, Narayana Narasimhan, Pingkuan Zhang, Karthik Venkatakrishnan, Neeraj Gupta
Format:	Article
Language:	English
Published:	Wiley 2024-04-01
Series:	CPT: Pharmacometrics & Systems Pharmacology
Online Access:	https://doi.org/10.1002/psp4.13106

Similar Items

Population pharmacokinetic and exposure‐response analyses from ALTA‐1L: Model‐based analyses supporting the brigatinib dose in ALK‐positive NSCLC
by: Neeraj Gupta, et al.
Published: (2022-05-01)

Addressing drug safety of maternal therapy during breastfeeding using physiologically‐based pharmacokinetic modeling
by: Xian Pan, et al.
Published: (2022-05-01)

Physiologically‐based pharmacokinetic model of sparsentan to evaluate drug–drug interaction potential
by: Nikunjkumar K. Patel, et al.
Published: (2024-02-01)

Comprehensive Physiologically Based Pharmacokinetic Model to Assess Drug–Drug Interactions of Phenytoin
by: Leyanis Rodriguez-Vera, et al.
Published: (2023-10-01)

Application of Physiologically Based Pharmacokinetic Modeling to Evaluate the Drug–Drug and Drug–Disease Interactions of Apatinib
by: Hongrui Liu, et al.
Published: (2021-11-01)

Investigation into the Formation of Impurities during the Optimization of Brigatinib
by: Aofeng Guo, et al.
Published: (2020-11-01)

Physiologically‐Based Pharmacokinetic Model‐Informed Drug Development for Fenebrutinib: Understanding Complex Drug‐Drug Interactions
by: Yuan Chen, et al.
Published: (2020-06-01)

Evaluation of drug–drug interaction potential for pemigatinib using physiologically based pharmacokinetic modeling
by: Tao Ji, et al.
Published: (2022-07-01)

Physiological and Pharmacokinetic Alterations and Drug-Nutrient Interactions During Pregnancy
by: Gözde Ede, et al.
Published: (2017-09-01)

Physiologically‐based pharmacokinetic modeling for primary metabolites of CYP3A and P‐glycoprotein inhibitors in drug–drug interactions: Should we assume the free drug hypothesis?
by: Shinji Yamazaki, et al.
Published: (2023-01-01)

Population pharmacokinetic/pharmacodynamic joint modeling of ixazomib efficacy and safety using data from the pivotal phase III TOURMALINE‐MM1 study in multiple myeloma patients
by: Jaydeep K. Srimani, et al.
Published: (2022-08-01)

A comprehensive review on Brigatinib – A wonder drug for targeted cancer therapy in non-small cell lung cancer
by: Silky Bedi, et al.
Published: (2018-09-01)

Pharmacokinetic Drug–Drug Interactions and Herb–Drug Interactions
by: Min-Koo Choi, et al.
Published: (2021-04-01)

Physiologically‐based pharmacokinetic modeling of prominent oral contraceptive agents and applications in drug–drug interactions
by: Gareth J. Lewis, et al.
Published: (2024-04-01)

Prediction of Drug–Drug Interaction Potential of Tegoprazan Using Physiologically Based Pharmacokinetic Modeling and Simulation
by: Deok Yong Yoon, et al.
Published: (2021-09-01)

A Physiologically Based Pharmacokinetic Model of Ketoconazole and Its Metabolites as Drug–Drug Interaction Perpetrators
by: Fatima Zahra Marok, et al.
Published: (2023-02-01)

Potential drug-drug interaction of olverembatinib (HQP1351) using physiologically based pharmacokinetic models
by: Zhiheng Yu, et al.
Published: (2022-12-01)

Application of physiologically‐based pharmacokinetic model approach to predict pharmacokinetics and drug–drug interaction of rivaroxaban: A case study of rivaroxaban and carbamazepine
by: Lien Thi Ngo, et al.
Published: (2022-11-01)

Physiologically based pharmacokinetic modeling of tacrolimus for food–drug and CYP3A drug–drug–gene interaction predictions
by: Helena Leonie Hanae Loer, et al.
Published: (2023-05-01)

Physiologically‐based pharmacokinetic modeling of the drug–drug interaction between ivacaftor and lefamulin in cystic fibrosis patients
by: Magali Amiel, et al.
Published: (2024-04-01)

Application of physiologically based pharmacokinetic modeling in predicting drug–drug interactions for sarpogrelate hydrochloride in humans
by: Min JS, et al.
Published: (2016-09-01)

Physiologically‐based pharmacokinetic modeling for investigating the effect of simeprevir on concomitant drugs and an endogenous biomarker of OATP1B
by: Shinji Nakayama, et al.
Published: (2023-10-01)

A Physiologically-Based Pharmacokinetic Framework for Prediction of Drug Exposure in Malnourished Children
by: Erik Sjögren, et al.
Published: (2021-02-01)

Application of Physiologically‐Based Pharmacokinetic Modeling to Predict Gastric pH‐Dependent Drug–Drug Interactions for Weak Base Drugs
by: Zhongqi Dong, et al.
Published: (2020-08-01)

Increasing application of pediatric physiologically based pharmacokinetic models across academic and industry organizations
by: Trevor N. Johnson, et al.
Published: (2022-03-01)

Utility of Physiologically Based Pharmacokinetic Modeling to Investigate the Impact of Physiological Changes of Pregnancy and Cancer on Oncology Drug Pharmacokinetics
by: Xinxin Yang, et al.
Published: (2023-12-01)

Direct Acting Antiviral Drugs: Pharmacokinetics and Drug-Drug Interactions
by: Marina Barakat, et al.
Published: (2022-12-01)

Drug–drug interaction prediction of ziritaxestat using a physiologically based enzyme and transporter pharmacokinetic network interaction model
by: Jeremy Perrier, et al.
Published: (2023-11-01)

Applied physiologically‐based pharmacokinetic modeling to assess uridine diphosphate‐glucuronosyltransferase‐mediated drug–drug interactions for Vericiguat
by: Sebastian Frechen, et al.
Published: (2024-01-01)

Evaluation for Potential Drug–Drug Interaction of MT921 Using In Vitro Studies and Physiologically–Based Pharmacokinetic Models
by: Hyo-jeong Ryu, et al.
Published: (2021-07-01)

Physiologically Based Pharmacokinetic Modelling of Cabozantinib to Simulate Enterohepatic Recirculation, Drug–Drug Interaction with Rifampin and Liver Impairment
by: Bettina Gerner, et al.
Published: (2021-05-01)

Physiologically‐based pharmacokinetic modeling to predict CYP3A4‐mediated drug‐drug interactions of finerenone
by: Thomas Wendl, et al.
Published: (2022-02-01)

Physiologically Based Pharmacokinetic Modeling and Simulation in Pediatric Drug Development
by: A R Maharaj, et al.
Published: (2014-11-01)

Prediction of Cyclosporin-Mediated Drug Interaction Using Physiologically Based Pharmacokinetic Model Characterizing Interplay of Drug Transporters and Enzymes
by: Yiting Yang, et al.
Published: (2020-09-01)

A Mechanistic, Enantioselective, Physiologically Based Pharmacokinetic Model of Verapamil and Norverapamil, Built and Evaluated for Drug–Drug Interaction Studies
by: Nina Hanke, et al.
Published: (2020-06-01)

Prediction of the Drug–Drug Interaction Potential between Tegoprazan and Amoxicillin/Clarithromycin Using the Physiologically Based Pharmacokinetic and Pharmacodynamic Model
by: Zhuodu Wei, et al.
Published: (2023-02-01)

Prediction of Drug–Drug Interactions Between Opioids and Overdosed Benzodiazepines Using Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation
by: Beihong Ji, et al.
Published: (2019-09-01)

Recommendations for the Design of Clinical Drug–Drug Interaction Studies With Itraconazole Using a Mechanistic Physiologically‐Based Pharmacokinetic Model
by: Yuan Chen, et al.
Published: (2019-09-01)

The role of brigatinib in crizotinib-resistant non-small cell lung cancer
by: Mezquita L, et al.
Published: (2018-01-01)

Physiologically‐based pharmacokinetic model‐based translation of OATP1B‐mediated drug–drug interactions from coproporphyrin I to probe drugs
by: Tatsuki Mochizuki, et al.
Published: (2022-06-01)